nanostring

Nanostring IPO disappoints as shares fall 20% on first day

It was a tough first day on the stock market for Seattle’s NanoString Technologies, with shares falling 19.4 percent on Wednesday as the stock closed at $8.06. The 138-person company, a maker of genomic analysis tools which spun out of genomics pioneer Leroy Hood’s Institute for Systems Biology in 2003, earlier this month planned to sell shares in the range of… Read More

nanostring

NanoString sets IPO range of $13-$15, plans to trade on Nasdaq under ticker NSTG

Seattle’s NanoString Technologies today set the terms for its upcoming initial public offering, with plans to sell shares in the range of $13 to $15 per share. The 138-person company, a maker of genomic analysis tools which spun out of genomics pioneer Leroy Hood’s Institute for Systems Biology in 2003, initially filed for an IPO last month…. Read More

nanostring

NanoString lands $15.3M for genetic analysis system

NanoString Technologies continues to rake in new capital, announcing today that it has raised $15.3 million from Morgan Stanley Expansion Capital and AllianceBernstein Alternative Investment Management Group. Existing investors, including Clarus Ventures, Draper Fisher Jurvetson, OVP Venture Partners, GE healthymagination Fund and BioMed Ventures, also participated in the financing. The deal follows a $20 million financing round… Read More

Keela Robison

Tech Moves: GameHouse taps Keela Robison; NanoString hires biotech vet Bruce Seely

Keela Robison is returning to her roots. After stints at Amazon.com and WhitePages, Robison is returning to RealNetworks’ and its GameHouse unit. Robison, who will serve as vice president of operations, will oversee the unit’s mobile and downloadable games business. She worked at RealNetworks as a general manager from 1998 to 2004 before moving on… Read More

nanostring

NanoString lands $20 million

NanoString Technologies, a maker of genomic analysis tools, has raised $20 million in venture capital financing in a deal led by GE, BioMed Ventures and former Genzyme CEO Henri Termeer. Existing investors Clarus Ventures, Draper Fisher Jurvetson and OVP Venture Partners also participated. The money will be used to grow the company’s life sciences tools business,… Read More